Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized treatment of metastatic castrate-resistant prostate cancer according to circulating tumor cell kinetics during chemotherapy
2016-002429-12Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jan 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Docetaxel arm with Cabazitaxel arm (2 arms). Primary endpoint: Biological activity of chemotherapy (primary). Started Jan 2018; status: completed.
02
Drugs
cabazitaxeldocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-002429-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002429-12.